Silmitasertib (Synonyms: CX-4945)

目录号: HY-50855 纯度: 99.94%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Silmitasertib (CX-4945) 是一种有效、可口服、高度选择性的 CK2 抑制剂，对 CK2α 和 CK2α' 的 IC₅₀值均为 1 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Silmitasertib Chemical Structure

CAS No. : 1009820-21-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥1250	In-stock
2 mg	￥650	In-stock
5 mg	￥1000	In-stock
10 mg	￥1600	In-stock
50 mg	￥5100	In-stock
100 mg	现货	询价
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Silmitasertib:

Silmitasertib sodium salt In-stock

MCE 顾客使用本产品发表的 38 篇科研文献

: Silmitasertib purchased from MCE. Usage Cited in: Oncol Rep. 2017 Feb;37(2):1141-1147. [Abstract]; CX-4945 increases the expression of apoptosis markers. Western blot analysis reveals that CX-4945 treatment increases the expression of cleaved PARP or cleaved caspase-3. CX-4945 treatment decreases the expression of Bcl-2 or Bcl-xL. The experiment is performed in triplicate, producing similar results.

: Silmitasertib purchased from MCE. Usage Cited in: Oncotarget. 2016 Aug 16;7(33):53191-53203. [Abstract]; MPNST cell lines show a decrease in CK2 activity in response to escalating CX-4945 concentrations (24 h) as measured by a western blot analysis using anti-CK2 substrate, and to undergo apoptosis as indicated by increased cleaved PARP.

Silmitasertib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Casein Kinase 亚型特异性产品:

查看所有亚型

CK1 CK2

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC₅₀ values of 1 nM against CK2α and CK2α'.

IC₅₀ & Target^[1]

CK2α

1 nM (IC₅₀)

CK2α'

1 nM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
786-0	IC₅₀	1 μM Compound: CX-4945	Inhibition of CK2 in human 786-0 cells assessed as decrease in Akt1 phosphorylation at Ser129 after 24 hrs by Western blot analysis Inhibition of CK2 in human 786-0 cells assessed as decrease in Akt1 phosphorylation at Ser129 after 24 hrs by Western blot analysis	[PMID: 30689946]
786-0	EC₅₀	1 μM Compound: CX-4945	Inhibition of CK2 in human 786-0 cells assessed as decrease in alpha-catenin phosphorylation at Ser641 after 24 hrs by Western blot analysis Inhibition of CK2 in human 786-0 cells assessed as decrease in alpha-catenin phosphorylation at Ser641 after 24 hrs by Western blot analysis	[PMID: 30689946]
786-0	EC₅₀	5.3 μM Compound: CX-4945	Inhibition of CK2 in human 786-0 cells assessed as reduction in STAT3 phosphorylation at Y705 after 24 hrs by Western blot analysis Inhibition of CK2 in human 786-0 cells assessed as reduction in STAT3 phosphorylation at Y705 after 24 hrs by Western blot analysis	[PMID: 30689946]
A-375	IC₅₀	3.9 μM Compound: 25n	Antiproliferative activity against human A375 cells after 4 days by alamar blue assay Antiproliferative activity against human A375 cells after 4 days by alamar blue assay	[PMID: 21174434]
A549	IC₅₀	11.6 μM Compound: CX-4945	Antiproliferative activity against human A549 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human A549 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
A549	IC₅₀	3 μM Compound: 25n	Antiproliferative activity against human A549 cells after 4 days by alamar blue assay Antiproliferative activity against human A549 cells after 4 days by alamar blue assay	[PMID: 21174434]
A549	IC₅₀	8.2 μM Compound: 31, CX-4945	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 22339433]
A549	CC₅₀	9.9 μM Compound: CX-4945	Cytotoxicity against human A549 cells after 72 hrs by MTS assay Cytotoxicity against human A549 cells after 72 hrs by MTS assay	[PMID: 26850376]
BXPC-3	IC₅₀	4.4 μM Compound: 25n	Antiproliferative activity against human BxPC3 cells after 4 days by alamar blue assay Antiproliferative activity against human BxPC3 cells after 4 days by alamar blue assay	[PMID: 21174434]
HCT-116	IC₅₀	13.21 μM Compound: CX-4945	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33834781]
HCT-116	IC₅₀	2.2 μM Compound: 25n	Antiproliferative activity against human HCT116 cells after 4 days by alamar blue assay Antiproliferative activity against human HCT116 cells after 4 days by alamar blue assay	[PMID: 21174434]
HCT-116	GI₅₀	4.8 μM Compound: CX4945	Growth inhibition of human HCT116 cells measured after 72 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells measured after 72 hrs by sulforhodamine B assay	[PMID: 36426237]
HCT-116	IC₅₀	5.2 μM Compound: 31, CX-4945	Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 22339433]
HeLa	EC₅₀	2.1 μM Compound: CX-4945	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay	[PMID: 34323071]
Hs-578T	IC₅₀	13.1 μM Compound: 25n	Antiproliferative activity against human Hs 578T cells after 4 days by alamar blue assay Antiproliferative activity against human Hs 578T cells after 4 days by alamar blue assay	[PMID: 21174434]
HT-22	IC₅₀	21.3 μM Compound: 9; CX-4945	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 36876904]
HT-29	IC₅₀	16 μM Compound: CX-4945	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33834781]
Jurkat	IC₅₀	0.1 μM Compound: 25n	Inhibition of CK2 in human Jurkat cells assessed as inhibition of [gamma33P]ATP incorporation into substrate by luminescence assay Inhibition of CK2 in human Jurkat cells assessed as inhibition of [gamma33P]ATP incorporation into substrate by luminescence assay	[PMID: 21174434]
Jurkat	IC₅₀	2.5 μM Compound: 25n	Antiproliferative activity against human Jurkat cells after 4 days by alamar blue assay Antiproliferative activity against human Jurkat cells after 4 days by alamar blue assay	[PMID: 21174434]
Jurkat	CC₅₀	4.5 μM Compound: CX-4945	Antiproliferative activity against human Jurkat cells after 1 to 3 days by MTS assay Antiproliferative activity against human Jurkat cells after 1 to 3 days by MTS assay	[PMID: 23711832]
K562	IC₅₀	5.3 μM Compound: 25n	Antiproliferative activity against human K562 cells after 4 days by alamar blue assay Antiproliferative activity against human K562 cells after 4 days by alamar blue assay	[PMID: 21174434]
K562	CC₅₀	7 μM Compound: CX-4945	Antiproliferative activity against human K562 cells after 1 to 3 days by MTS assay Antiproliferative activity against human K562 cells after 1 to 3 days by MTS assay	[PMID: 23711832]
L02	IC₅₀	22.98 μM Compound: CX-4945	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33834781]
LNCaP	IC₅₀	4.59 μM Compound: CX4945	Cytotoxicity against human LNCAP cells assessed as cell viability after 4 days by CCK8 method Cytotoxicity against human LNCAP cells assessed as cell viability after 4 days by CCK8 method	[PMID: 22832316]
LNCaP	IC₅₀	4.7 μM Compound: 25n	Antiproliferative activity against human LNCAP cells after 4 days by alamar blue assay Antiproliferative activity against human LNCAP cells after 4 days by alamar blue assay	[PMID: 21174434]
LNCaP	IC₅₀	6.52 μM Compound: CX-4945	Antiproliferative activity against human LNCAP cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human LNCAP cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
MCF7	IC₅₀	15.31 μM Compound: CX-4945	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33834781]
MCF7	IC₅₀	6.5 μM Compound: 31, CX-4945	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 22339433]
MCF7	IC₅₀	8.9 μM Compound: 25n	Antiproliferative activity against human MCF7 cells after 4 days by alamar blue assay Antiproliferative activity against human MCF7 cells after 4 days by alamar blue assay	[PMID: 21174434]
MCF7	IC₅₀	9.41 μM Compound: CX-4945	Antiproliferative activity against human MCF7 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human MCF7 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
MDA-MB-231	IC₅₀	14.25 μM Compound: 18; CX-4945	Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay	[PMID: 34908415]
MDA-MB-231	IC₅₀	6.4 μM Compound: CX-4945	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 4 days by Alamar blue assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 4 days by Alamar blue assay	[PMID: 37077385]
MDA-MB-231	IC₅₀	6.4 μM Compound: 25n	Antiproliferative activity against human MDA-MB-231 cells after 4 days by alamar blue assay Antiproliferative activity against human MDA-MB-231 cells after 4 days by alamar blue assay	[PMID: 21174434]
MDA-MB-468	IC₅₀	20.92 μM Compound: 18; CX-4945	Antiproliferative activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells incubated for 24 hrs by MTT assay	[PMID: 34908415]
MIA PaCa-2	IC₅₀	1.1 μM Compound: 25n	Antiproliferative activity against human MIAPaCa2 cells after 4 days by alamar blue assay Antiproliferative activity against human MIAPaCa2 cells after 4 days by alamar blue assay	[PMID: 21174434]
MV4-11	CC₅₀	3 μM Compound: CX-4945	Antiproliferative activity against human MV4-11 cells after 1 to 3 days by MTS assay Antiproliferative activity against human MV4-11 cells after 1 to 3 days by MTS assay	[PMID: 23711832]
NCI-H1299	IC₅₀	2.4 μM Compound: 25n	Antiproliferative activity against human H1299 cells after 4 days by alamar blue assay Antiproliferative activity against human H1299 cells after 4 days by alamar blue assay	[PMID: 21174434]
PBMC	CC₅₀	50 μM Compound: CX-4945	Cytotoxicity against human PHA-activated PBMC after 1 to 3 days by MTS assay Cytotoxicity against human PHA-activated PBMC after 1 to 3 days by MTS assay	[PMID: 23711832]
PC-3	IC₅₀	10.87 μM Compound: CX-4945	Antiproliferative activity against human PC3 cells incubated for 96 hrs by resazurin assay Antiproliferative activity against human PC3 cells incubated for 96 hrs by resazurin assay	[PMID: 32435375]
PC-3	IC₅₀	12.75 μM Compound: CX-4945	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33834781]
PC-3	IC₅₀	2.1 μM Compound: 25n	Antiproliferative activity against human PC3 cells after 4 days by alamar blue assay Antiproliferative activity against human PC3 cells after 4 days by alamar blue assay	[PMID: 21174434]
Sf9	IC₅₀	1.8 μM Compound: Silmitasertib	Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP	[PMID: 24681986]
T-24	IC₅₀	12.92 μM Compound: CX-4945	Cytotoxicity against human T24 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human T24 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33834781]
U-937	CC₅₀	4.2 μM Compound: CX-4945	Antiproliferative activity against human U937 cells after 1 to 3 days by MTS assay Antiproliferative activity against human U937 cells after 1 to 3 days by MTS assay	[PMID: 23711832]

体外研究
(In Vitro)

Silmitasertib (CX-4945) 可使癌细胞相较于正常细胞发生细胞周期阻滞并选择性诱导其凋亡，减弱 PI3K/Akt 信号传导，并且 Silmitasertib (CX-4945) 的抗增殖活性与 CK2α 催化亚基的表达水平相关，同时减弱 PI3K/Akt 信号传导^[1]。Silmitasertib (CX-4945) 与 PS-341 联合使用可防止白血病细胞参与功能性未折叠蛋白反应 (UPR)，以缓冲 PS-341 介导的内质网腔蛋白毒性应激，并降低促存活内质网伴侣 BIP/Grp78 表达^[2]。
Silmitasertib (CX-4945) 通过下调 CK2 表达并抑制 CK2 介导的 PI3K/Akt/mTOR 信号通路的激活，诱导血液肿瘤的细胞毒性和凋亡，并发挥抗增殖作用^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Silmitasertib (CX-4945) (25 or 75 mg/kg, p.o.) 耐受性良好，并在小鼠异种移植模型中表现出强大的抗肿瘤活性，同时伴随基于作用机制的生物标志物磷酸化 p21 (T145) 的减少^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

349.77

Formula

C₁₉H₁₂ClN₃O₂

CAS 号

1009820-21-6

性状

固体

颜色

Yellow to orange

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 35 mg/mL (100.07 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

0.1 M NaOH 中的溶解度 : 33.33 mg/mL (95.29 mM; ultrasonic and adjust pH to 9 with NaOH)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8590 mL	14.2951 mL	28.5902 mL
5 mM	0.5718 mL	2.8590 mL	5.7180 mL
10 mM	0.2859 mL	1.4295 mL	2.8590 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (5.95 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.95 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 0.5% CMC-Na/0.5% Tween-80 in Saline water
Solubility: 9.95 mg/mL (28.45 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.94%

选择批次：

Data Sheet (647 KB) SDS (393 KB)

COA (191 KB) LCMS (98 KB) 元素分析报告 (208 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98. [Content Brief]

[2]. Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40. [Content Brief]

[3]. Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70. [Content Brief]

Cell Assay ^[1]	Various cell lines are seeded at a density of 3,000 cells per well 24 hours prior to treatment, in appropriate media, and then treated with indicated concentrations of Silmitasertib (CX-4945). Suspensions cells are seeded and treated on the same day. Following 4 days of incubation, Alamar Blue (20 μL, 10% of volume per well) is added and the cells are further incubated at 37°C for 4-5 hours. Fluorescence with excitation wavelength at 530-560 nm and emission wavelength at 590 nm is measured. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Xenografts are initiated by subcutaneous injection of BxPC-3 cells into the right hind flank region of each mouse or BT-474 cells are injected into the mammary fat pad of mice implanted with estrogen pellets. When tumors reach a designated volume of 150-200 mm³, animals are randomized and divided into groups of 9 to 10 mice per group. Silmitasertib (CX-4945) is administered by oral gavage twice daily at 25 or 75 mg/kg for 31 and 35 consecutive days for the BT-474 and BxPC-3 models, respectively. Tumor volumes and body weights are measured twice weekly. The length and width of the tumor are measured with calipers and the volume calculated using the following formula: tumor volume=(length × width²)/2. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98. [Content Brief] [2]. Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40. [Content Brief] [3]. Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70. [Content Brief]

Silmitasertib 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

0.1 M NaOH / DMSO	1 mM	2.8590 mL	14.2951 mL	28.5902 mL	71.4755 mL
	5 mM	0.5718 mL	2.8590 mL	5.7180 mL	14.2951 mL
	10 mM	0.2859 mL	1.4295 mL	2.8590 mL	7.1476 mL
	15 mM	0.1906 mL	0.9530 mL	1.9060 mL	4.7650 mL
	20 mM	0.1430 mL	0.7148 mL	1.4295 mL	3.5738 mL
	25 mM	0.1144 mL	0.5718 mL	1.1436 mL	2.8590 mL
	30 mM	0.0953 mL	0.4765 mL	0.9530 mL	2.3825 mL
	40 mM	0.0715 mL	0.3574 mL	0.7148 mL	1.7869 mL
	50 mM	0.0572 mL	0.2859 mL	0.5718 mL	1.4295 mL
	60 mM	0.0477 mL	0.2383 mL	0.4765 mL	1.1913 mL
	80 mM	0.0357 mL	0.1787 mL	0.3574 mL	0.8934 mL
DMSO	100 mM	0.0286 mL	0.1430 mL	0.2859 mL	0.7148 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Silmitasertib1009820-21-6CX-4945CX4945CX 4945Casein KinaseAutophagyInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Silmitasertib (Synonyms: CX-4945)

Customer Review

Other Forms of Silmitasertib:

MCE 顾客使用本产品发表的 38 篇科研文献

Silmitasertib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Casein Kinase 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Silmitasertib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Silmitasertib (Synonyms: CX-4945)

Customer Review

Other Forms of Silmitasertib:

Silmitasertib 相关抗体

MCE 顾客使用本产品发表的 38 篇科研文献

Silmitasertib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Casein Kinase 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Silmitasertib 相关抗体:

摩尔计算器

稀释计算器

Silmitasertib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z